| Number of | Percent with outcome | |||||
|---|---|---|---|---|---|---|
| Outcome - daily dose | Studies | Participants | Pregabalin | Placebo | Relative risk (95% CI) | NNH (95% CI) |
| Somnolence | ||||||
| 600 mg | 2 | 177 | 42 | 17 | 2.5 (1.5 to 4.1) | 4.0 (2.6 to 8.3) |
| Dizziness | ||||||
| 600 mg | 2 | 177 | 27 | 14 | 2.0 (1.1 to 3.6) | 7.8 (4.1 to 82) |
| Adverse event discontinuation | ||||||
| 600 mg | 2 | 177 | 20 | 14 | 1.5 (0.7 to 2.8) | not calculated |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.